Tryptamine Therapeutics has reached a milestone in development of its novel IV-infused psilocin formulation TRP-8803, with the drug meeting all phase 1b study objectives. Tryptamine Therapeutics ...

Tryptamine's TRP-8803 advances to Phase 2 trials, offering faster onset and safer control over psychedelic treatments via IV infusion. Phase 1b results highlight TRP-8803's precise dosing, safety ...

The placement is a bright spot in an otherwise quiet period for psychedelics industry financing. Australian biotech firm Tryptamine Therapeutics Limited (ASX: TYP) secured A$6 million in new funding ...

Tryptamine Therapeutics (AU:TYP) has released an update. Don't Miss our Black Friday Offers: Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top ...

all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Tryptamine Therapeutics has announced successful completion of ...

Tryptamine Therapeutics (AU:TYP) has released an update. Tryptamine Therapeutics Limited (ASX: TYP) has requested a trading ...

Tryptamine Therapeutics (AU:TYP) has released an update. Tryptamine Therapeutics Limited is offering 10,000 shares at $0.02 each, aiming to remove trading restrictions on shares issued before the ...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Fraser Palamara dissects the $6 million raising completed today by biotech company ...

Tryptamine receives firm commitments to raise $6m in placement strongly supported by new and existing stakeholders Placement cornerstoned by Merchant Biotech Fund and biotech investor Dr Daniel ...

In this episode, host Fraser Palamara dissects the $6 million raising completed today by biotech company Tryptamine Therapeutics (ASX:TYP). Money garnered from the placement, priced at 2c per ...